Potvin C in the EU [Two-Stage / GS Designs]

posted by ElMaestro  – Belgium?, 2013-04-17 02:31 (2669 d 14:55 ago) – Posting: # 10425
Views: 35,478

Hi Hötzi,

» new experiences from an ongoing MRP. Two studies (first one in two groups due to logistic reasons), Method C (!), all metrics in both studies passed in stage 1 (>80% power in the interim, no α-adjustment = 90% CIs).

Ahhh... MRP - a relic from the bygone ages when your grandad walked around in the snowy alps with bow and arrows looking for deer.

» Studies’ models in stage 1:
  1. Fixed:  sequence, period, treatment, group, group × treatment
    » Random: subject(sequence)
  2. Fixed:  sequence, period, treatment
    » Random: subject(sequence)
Accepted by Germany (RMS); no comments from Austria, Denmark, Sweden, and The Netherlands. Spain: “Statistical analysis should be GLM. Please justify. Please provide the NOL.”
» OK, I will repeat the analyses with all fixed effects (sigh; identical CIs…). ;-)

Anything to please the assessor. I have a feeling the assessor means LM but might not know what that really means since every LM in SAS is done via PROC GLM.
But honestly, group x treatment?? I'd rather not go down that road. I hope you do not make precedence.

» BTW, does anybody know what “NOL” means?

I am fairly sure it is either "No Objection Lertificate" or "Nixon's Obstructive Leprosy". I don't see what else it could possibly be.

I could be wrong, but...

Best regards,

"Pass or fail" (D. Potvin et al., 2008)

Complete thread:

 Admin contact
20,977 posts in 4,374 threads, 1,460 registered users;
online 26 (1 registered, 25 guests [including 16 identified bots]).
Forum time: Friday 17:27 CEST (Europe/Vienna)

When someone says his conclusions are objective,
he means that they are based on prejudices
which many other people share.    Celia Green

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz